|
Post by marriott on May 10, 2021 22:57:11 GMT
Very sobering call requiring shareholder reflection of the purpose and goal of our individual investment in Novavax . And yes, watching the NVAX share price decline is very painful .
Some thoughts :
Cash on hand
Look , as of December 31, 2020, Novavax had $806.4 million in cash, cash equivalents... compared to $2 billion in cash, cash equivalents.... as of March 31, 2021 . So the financial resources to reach the market by the end of this year will be available.
EUA
The company detailed various accomplishments during the first quarter 2021 in the areas of Clinical development , Manufacturing /Supply and Regulatory pathways. We learned that the company intends “ to file for authorization with the U.S. Food and Drug Administration (FDA), the UK Medicines and Healthcare products Regulatory Agency (MHRA) and the European Medicines Agency (EMA) in Europe in the third quarter of 2021 . “
Time
Hard to see any strong catalysts prior to EUA grants . So time is a significant factor in our CoVid-19 related world. It is also a significant factor in our own individual financial goals .
Production
CEO Erck cited some production issues and stated they were now resolved. I would have advised him to state specifically how the issues they were resolved and give a blueprint of the reasons they will not reoccur.
I believe that Novavax will succeed in reaching the market . If you believe this to be true , the question many of us are asking is do I have the patience and the financial wherewithal to stay on the journey with Novavax.
I do !
|
|